210 results about "Cholic acid" patented technology

The invention relates to the field of biomedicine, particularly provides a copper-based nano-enzyme as well as a preparation method and application thereof, and aims to solve the problems that in the prior art, clinical treatment on primary sclerosing cholangitis (PSC) is difficult in diagnosis and lacks of effective treatment drugs. The copper-based nano-enzyme comprises a nano-enzyme carrier and a copper-based nano-enzyme, wherein the nano-enzyme carrier is a two-dimensional nanosheet formed by copper ions, gallic acid and ursodesoxycholic acid through coordinate bonds; the probe molecule is a cyanine dye molecule connected to the surface of the nano-enzyme carrier through a covalent bond; wherein the fluorescence intensity of the copper-based nano enzyme is enhanced after the action of the alkaline phosphatase. The three functions of alkaline phosphatase responsive diagnosis, nano-enzyme catalytic treatment and ursodesoxycholic acid hepatic targeting are innovatively and synergistically integrated into one nano platform, the treatment function can be executed while specific imaging diagnosis is performed on diseases, and a new strategy is provided for diagnosis and treatment of diseases such as PSC.

The invention belongs to the technical field of microorganisms, and particularly relates to bacillus cereus as well as a culture and application thereof. The preservation number of the bacillus cereus AK-LY1 is CCTCC (China Center For Type Culture Collection) NO: M 2025756. The bacillus cereus AK-LY1 disclosed by the invention is excellent in trypsin resistance, good in cholate resistance, acid resistance and high temperature resistance, good in inhibition performance on antibiotics such as strong penicillin and chloramphenicol, and relatively good in adhesion capacity in intestinal tracts, and provides a relatively good microecological preparation reference basis for expanding a bacillus cereus resource library and applying the bacillus cereus.

The invention discloses a biochemical immunodetection device and a biochemical immunodetection method for ursodesoxycholic acid reduzate, and belongs to the technical field of ursodesoxycholic acid reduzate detection. The ursodesoxycholic acid reduzate detection device comprises a detection box and a lifter at the bottom of the detection box, a dissolution preparation part and a centrifugal part are arranged in the detection box, and the dissolution preparation part can fully dissolve an ursodesoxycholic acid reduzate-containing medicament; the centrifugal part is used for carrying out precipitation separation on the dissolved medicament; the detector can accurately collect fluorescence signals of the immune complex; according to the ursodesoxycholic acid reduzate detection device, the integrated operation of detection test tube fixing, cover opening and transferring, medicament adding, cover closing and plug sealing and dissolving is achieved, the steps of automatic medicament filling, sealing and the like are achieved, the medicament preparation efficiency is greatly improved, efficient and accurate detection of ursodesoxycholic acid reduzate is further achieved, and the detection efficiency is improved. And complex and tedious manual operation is avoided, and the situation that the sample is easily polluted by manual operation is avoided.

The invention relates to the technical field of health wine preparation, and discloses a multi-effect synergistic enhanced bear gall body-building wine compound preparation process which comprises the following steps: taking sorghum, corn and fructus lycii as fermentation base materials, and carrying out double-strain synergistic fermentation by adopting saccharomyces cerevisiae and lactobacillus plantarum; adding fresh ursodesoxycholic acid during fermentation, carrying out in-situ enzymatic debinding conversion by using a compound enzyme system generated by a fermentation system, and converting the bound bile acid into free ursodesoxycholic acid; after fermentation, distilling to obtain raw wine; a molecularly imprinted polymer prepared by taking a wolfberry polyphenol key monomer as a template molecule is adopted to carry out targeted anchoring refining on raw wine, selective capture and enrichment of wolfberry polyphenol are carried out, and finally aging is carried out to obtain a finished product. According to the method disclosed by the invention, upstream double-strain fermentation in-situ enzymatic conversion and downstream molecular imprinting targeted refining are systematically integrated, so that the technical contradictions that the conversion rate of combined bile acid is low and a large amount of polyphenol functional components are synchronously lost during purification and impurity removal in a traditional process are solved.

This invention belongs to the field of diagnostic testing technology. Addressing the problem that existing gestational diabetes screening methods may miss the optimal time for early intervention, leading to the failure to promptly detect and manage some potentially hyperglycemic pregnant women, increasing the risk of adverse maternal and fetal outcomes, this invention proposes a plasma metabolic biomarker for the early diagnosis or prediction of gestational diabetes and its application. This plasma metabolic biomarker is at least one of L-lysine, propargylglycine, N6-acetyl-L-lysine, cyclic leucine, and glycine-deoxycholic acid. The five plasma metabolic biomarkers provided by this invention can be applied to the early diagnosis or prediction of gestational diabetes, and are of great significance for the prevention or treatment of gestational diabetes.

The invention discloses an application of astaxanthin in preparation of a regulator for improving the gentisic acid level. On the basis of non-targeted metabonomics analysis, it is found for the first time that in the SAP pathogenesis process, the level of a flora metabolite, namely gentisic acid (GA), in intestinal contents is remarkably reduced, and in-vivo gentisic acid level can be remarkably callback through astaxanthin intervention. Further research proves that exogenous supplement of gentisic acid can effectively simulate the protection effect of astaxanthin, including improvement of pancreatic tissue pathological damage, reduction of serum lipase and amylase activity, and inhibition of systemic inflammatory response (down-regulation of IL-1beta, IL-6 and TNF-alpha and up-regulation of IL-10). The invention not only discloses a new mechanism that astaxanthin plays a therapeutic role through an'intestinal flora-metabolite 'axis, but also determines that gentisic acid is used as a novel drug target for treating SAP, and constructs a new method for screening drugs for treating SAP according to the novel drug target.

A curcumin nanococrystal composition including curcumin, a coformer, and a stabilizer. The coformer may include at least one of 3,5-dinitrobenzoicacid, gentisic acid, phloroglucinol, 4,4-bipyridine, tartaric acid, citric acid, and gallic acid. The curcumin nanococrystal composition has a particle size less than 10 nm, and the curcumin has a water-solubility between 5 mg / ml and 20 mg / ml.

The invention relates to the field of biological catalysis, and discloses a method and a device for generating ursodesoxycholic acid through continuous flow catalysis of chenodeoxycholic acid. Comprising the following steps: (1) in the presence of first immobilized cells, carrying out a first catalytic reaction on a reaction system containing chenodeoxycholic acid to obtain a first product, the first immobilized cells expressing 7 alpha-hydroxysteroid dehydrogenase and lactic dehydrogenase; the concentration of the chenodeoxycholic acid in the reaction system is 40 to 70 mM; (2) adjusting the pH value of the first product to 8-9, and then in the presence of a second immobilized cell, carrying out a second catalytic reaction on the first product after the pH value is adjusted to obtain ursodesoxycholic acid, and the second immobilized cell expresses 7 beta-hydroxysteroid dehydrogenase and glucose dehydrogenase. According to the method, the stable activity of a catalytic system is kept, efficient conversion of high-concentration CDCA is achieved, meanwhile, precipitation of 7-KLCA is thoroughly avoided, and the synthesis efficiency, the product purity and the process continuity of UDCA are remarkably improved.

The application belongs to the field of neuropharmacology and medicine, and particularly relates to application of taurine cholic acid in preparation of a drug for preventing or treating Alzheimer's disease. Through animal model experiment verification, the A beta lateral ventricle injection is used to prepare an AD mouse model, and after oral administration of TCA for 2 weeks, cognitive behavior and pathological indexes are significantly improved.

This invention relates to the field of biomedical technology, specifically to the application of 6-ketolithocholic acid in the preparation of drugs that reduce fat deposition. The 6-ketolithocholic acid in this invention inhibits the accumulation of lipid droplets in adipocytes and suppresses gene expression in the PPARγ pathway involved in lipid synthesis, thereby achieving the function of reducing fat deposition. The structural formula of the 6-ketolithocholic acid is: [Insert structural formula here].

Methods are provided for effectively distinguishing the abilities of a human liver and an extracorporeal liver in an extracorporeal liver perfusion system to extract cholate and, thus, measure relative liver function.

The invention provides a composition containing bile acid and bifidobacterium animalis subsp. Lactis for improving tear stains of dogs and cats. The composition is prepared from the bile acid and the bifidobacterium animalis subsp. Lactis ZYhyy-017, and the composition is prepared from the bile acid, the bifidobacterium animalis subsp. Lactis ZYhyy-017, the bifidobacterium animalis subsp. Lactis ZYhyy-017 and the bifidobacterium animalis subsp. Lactis ZYhyy-017. The bifidobacterium animalis subsp. Lactis ZYhyy-017 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.37292, and the preservation date is January 6, 2026. The bifidobacterium animalis subsp. Lactis ZYhyy-017 is preserved in the China General Microbiological Culture Collection Center (CGMCC). The bile acid is chenodeoxycholic acid (CDCA). The composition regulates and controls a bile acid-porphyrin metabolic pathway in a targeted manner through the synergistic effect of bile acid and bifidobacterium animalis subsp. Lactis ZYhyy-017, porphyrin metabolism in pets is regulated from the source, intestinal and liver axis metabolism and liver functions are optimized, long-acting and safe improvement of tear stains of dogs and cats is achieved, and the composition has a wide application prospect. Meanwhile, the technical blank that bile acid and specific probiotics are synergistically applied to the field of tear stain improvement of dogs and cats is filled up, and the actual requirement for tear stain root improvement in pet feeding is met.

The invention provides application of taurochenodeoxycholic acid in preparation of a medicine for preventing and / or treating Fuchs corneal endothelial dystrophy, and particularly belongs to the technical field of medicine preparation. The invention provides an application of taurochenodeoxycholic acid in preparation of a medicine for preventing and / or treating Fuchs corneal endothelial dystrophy. Test results show that taurochenodeoxycholic acid can realize prevention and / or treatment of corneal endothelial cell injury caused by UVA; the number reduction, activity reduction, oxidative stress, ROS level rise and mitochondrial membrane potential drop of corneal endothelial cells caused by UVA are relieved; mitochondrial biological energy deficiency caused by UVA is relieved; and the prevention and / or treatment of the Fuchs corneal endothelial dystrophy are / is realized by activating a Ca < 2 + > signal channel.

The invention belongs to the technical field of detection and analysis, and provides an HPLC detection method for taurocholic acid in snake gall bulbus fritilariae liquid, which comprises the following steps: collecting chromatograms of a test sample and a reference substance through HPLC, and judging whether a co-outflow phenomenon exists or not; if the co-outflow phenomenon occurs, interference proportion analysis is carried out, and main interferents are identified; the judged main interferents are removed; carrying out retention analysis to obtain a taurocholic acid retention rate, judging whether the taurocholic acid retention rate accords with expectation or not based on the taurocholic acid retention rate, and if not, judging whether a trailing signal is triggered or not; if the trailing signal is triggered, performing cause analysis to determine the cause of triggering the trailing signal; when the optimal methanol proportion is obtained, a comprehensive detection signal is triggered; if the comprehensive detection signal is triggered, performing comprehensive adaptation analysis of the HPLC detection method to obtain an adaptation index, and evaluating the comprehensive performance of the HPLC detection method according to the adaptation index; and the accuracy of HPLC taurocholic acid detection is effectively improved.

The application provides a preparation method and application of a near-infrared two-region fluorescent sensor, and chiral single-walled carbon nanotubes are separated by using a double water phase extraction method; materials in the separation process include deionized water, polyethylene glycol, dextran, sodium dodecyl sulfate, sodium deoxycholate and cholic acid sodium hydrate; the chiral single-walled carbon nanotubes are dispersed and mixed with 4-nitrobenzene tetrafluoroboric acid diazonium salt to obtain the fluorescent sensor; high-purity (6,5)-SWCNT is efficiently and simply separated by using the double water phase extraction technology, the prepared SWCNT-NBD nanomaterial has good optical performance, including bright light emission in the near-infrared two-region, has good penetration capacity on biological tissues, the fluorescent detector (SWCNT-NBD) has low detection line, wide linear range, good selectivity on DA, and is convenient to prepare and low in cost.

This invention provides a 7β-HSDH enzyme mutant, its encoding gene, and its applications. Through artificial mutation screening, 7α-HSDH and 7β-HSDH enzyme mutants with specific amino acid sequences were identified, resulting in improved enzyme activity and catalytic efficiency compared to wild-type 7α-HSDH and wild-type 7β-HSDH. This invention also provides a method for preparing ursodeoxycholic acid using the aforementioned 7α-HSDH and 7β-HSDH enzyme mutants, specifically using NADP... + A one-pot catalytic method for the conversion of chenodeoxycholic acid to ursodeoxycholic acid using NADPH-dependent 7α-HSDH enzyme mutants and NADPH-dependent 7β-HSDH enzyme mutants is employed. This method is simple, yields high product conversion, and can also achieve the conversion of the coenzyme NADP. + / NADPH's self-circulating regeneration eliminates the need for auxiliary enzymes and raw materials used in coenzyme regeneration, greatly reducing production costs and environmental pressure, and possessing enormous potential for industrial applications.

This invention relates to a traditional Chinese medicine combination for treating intrahepatic cholestasis, which is made from the following raw materials in parts by weight: Artemisia capillaris and Glycyrrhiza uralensis 5:1 and 3:1. This invention also provides the preparation of the above-mentioned medicine and its use in treating intrahepatic cholestasis. Its advantages are: the traditional Chinese medicine composition of this invention (Artemisia capillaris and Glycyrrhiza uralensis decoction) has a significant ameliorative effect on intrahepatic cholestasis (non-obstructive type) induced by a 1% CA-containing diet in mice. Artemisia capillaris and Glycyrrhiza uralensis decoction can alleviate weight loss in mice and improve liver necrosis; significantly reduce serum ALT and ALP levels in mice; reduce the content of total bile acids in the liver and decrease the proportion of toxic bile acid taurine deoxycholic acid (TDCA) in the bile acid pool; upregulate liver BSEP protein expression to promote bile acid efflux; and downregulate liver NLRP3 protein expression to alleviate liver necrosis.

The invention provides an impurity removal method of a chenodeoxycholic acid crude product, which comprises the following steps: dissolving the chenodeoxycholic acid crude product and glucose in a solvent, adding alkali to control the pH value of the system to be 8-10, and adding thiourea to react so as to convert 22-ene-chenodeoxycholic acid impurities into chenodeoxycholic acid. According to the impurity removal method provided by the invention, the 22-ene-chenodeoxycholic acid impurity in chenodeoxycholic acid can be effectively removed without adopting a heavy metal catalyst and the like, and the method is convenient to operate, mild in condition, low in production risk and suitable for large-scale industrial production.

This invention provides an amphiphilic carbon dot, a rapidly dispersible, ultra-stable foam system, and its preparation method, belonging to the field of oilfield chemistry. The preparation method of the amphiphilic carbon dot includes: dissolving cholic acid in a first solvent to obtain a hydrophobic precursor solution; dissolving chitosan oligomers in a second solvent to obtain a hydrophilic precursor solution; mixing the hydrophobic and hydrophilic precursor solutions in a closed reactor, allowing it to stand for 5-10 minutes, and then performing staged microwave treatment: 180-220W for 1-3 minutes, 450-550W for 2-5 minutes, and 80-120W for 4-8 minutes; cooling the reaction solution to room temperature, and then filtering, dialyzing, and freeze-drying to obtain the amphiphilic carbon dot. This invention, through the synergistic effect of amphiphilic carbon dots and surfactants, can achieve rapid dispersion to form uniform foam and maintain foam stability for a long time in high-salt environments, meeting the application requirements in high-salt scenarios.

The invention belongs to the technical field of biomedicine synthesis, and particularly relates to the technical field of chemical synthesis of natural drugs / prodrugs for controlling metabolic abnormalities such as blood sugar and blood fat. The invention provides a preparation method of a cholic acid derivative. The preparation method comprises the following steps: adding benzyl bromide into an alkaline solution containing cholic acid to obtain benzyl cholate; the method comprises the following steps: adding a dichloromethane solution containing acyl chloride into a dichloromethane solution containing benzyl cholate and 4-dimethylaminopyridine under protective gas to obtain a colorless oily product; and introducing hydrogen into the absolute ethyl alcohol in which the colorless oily product is dissolved to obtain the cholic acid derivative. The chemical synthesis of the cholic acid derivative is realized.

The present application relates to the application of Hhex agonists in promoting anti-tumor immunity. Specifically, the present application provides a pharmaceutical composition comprising chenodeoxycholic acid and an anti-PD-1 antibody. The present application also provides the use of chenodeoxycholic acid and an anti-PD-1 antibody in the preparation of a drug for promoting anti-tumor immunity. In addition, the present application also provides the use of chenodeoxycholic acid and an anti-PD-1 antibody in the preparation of a drug for treating tumors. The present application uses chenodeoxycholic acid to improve the tumor immune microenvironment and uses it to treat subcutaneous tumors, further verifying that the application of chenodeoxycholic acid can improve the tumor immune microenvironment.

Provided are pharmaceutical compositions comprising a combination therapy having therapeutically effective amounts of sodium 4-phenyIbutylate and tauroursodeoxycholic acid for the treatment of an ocular condition in a subject. Also provided herein are methods using the combination therapy, and a pharmaceutical composition thereof, for preventing or treating an ocular condition in a subject.

The application provides an amphiphilic carbon dot, a rapid dispersion ultra-stable foam system and a preparation method thereof, and belongs to the field of oil field chemistry, wherein the preparation method of the amphiphilic carbon dot comprises the following steps: dissolving cholic acid in a first solvent to obtain a hydrophobic phase precursor solution; dissolving chitosan oligomer in a second solvent to obtain a hydrophilic phase precursor solution; mixing the hydrophobic phase precursor solution and the hydrophilic phase precursor solution in a closed reactor, standing for 5-10 min, and performing phased microwave treatment: 180-220 W for 1-3 min, 450-550 W for 2-5 min, and 80-120 W for 4-8 min; cooling the reaction liquid to room temperature, and obtaining the amphiphilic carbon dot through filtration, dialysis and freeze-drying. Through the synergistic effect of the amphiphilic carbon dot and the surfactant, the application can realize rapid dispersion to form uniform foam, and can maintain the stability of the foam in a high-salt environment for a long time, thereby meeting the application requirements in a high-salt scene.

The invention provides bile acid for improving microgravity-induced glucose metabolism disorder and application of the bile acid, and belongs to the technical field of medicines. According to the invention, tauroursodeoxycholic acid (TUDCA) is utilized to effectively reduce the blood glucose level of a microgravity environment model mouse, improve the liver glucose metabolism function and inflammation state of the microgravity environment model mouse, and reduce the serum cholesterol level of the model mouse; a technical scheme which is high in safety and clear in targeting and has application potential is provided for intervention of metabolic abnormalities in the microgravity environment, and an experimental foundation is laid for development of related functional products or protective preparations.

The invention discloses application of a reagent for detecting a plasma metabolism marker combination in preparation of a product for diagnosing breast cancer, and belongs to the field of breast cancer markers. According to the application of the reagent for detecting the plasma metabolism marker combination in preparing the product for diagnosing the breast cancer, the plasma metabolism marker combination comprises dehydroepiandrosterone sulfate, acylcarnitine 12: 0 and taurodeoxycholic acid. The plasma metabolism marker combination has high specificity, high sensitivity and non-invasiveness when being used for breast cancer detection, so that a subject can conveniently and safely receive detection, and the plasma metabolism marker combination is suitable for screening and detection of large-scale common people and is beneficial to early screening, early diagnosis and early treatment of breast cancer.

The invention belongs to the technical field of animal model construction, and particularly relates to a method for constructing a silicosis-related atherosclerosis animal model. Comprising the following steps: after adaptive feeding of healthy mice, intragastric ursodeoxycholic acid is performed once, the mice are fed with high-fat feed and periodically subjected to nasal drop treatment by 50mg / mL SiO2 suspension for more than 10 weeks, and during the period, the mice freely eat and drink water; wherein the specific operation of the periodic 50mg / mL SiO2 suspension nasal drop is as follows: the periodic 50mg / mL SiO2 suspension nasal drop is carried out once every 3-4 days, and 30-50mu L of the periodic 50mg / mL SiO2 suspension nasal drop is taken each time; the intragastric administration dosage of ursodeoxycholic acid is that 100-200 mg of ursodeoxycholic acid is administered to each kilogram of mouse body weight. According to the invention, a triple induction strategy of silicon dioxide exposure, high fat diet and induction factor stimulation is adopted, two pathological characteristics of silicosis and atherosclerosis can be successfully and stably generated in a C57BL / 6J mouse, and relevance of silicosis and atherosclerosis can be simulated at the same time.

This invention relates to the field of pharmaceutical analysis technology, specifically to a method for determining the content of deoxycholic acid injection. The detection method employs high-performance liquid chromatography (HPLC) with an ultraviolet (UV) detector. The HPLC chromatographic conditions are as follows: the column is an octadecylsilane-bonded silica column; the column dimensions are 4.6 × 150 mm, and the packing diameter is 3 μm; the detection wavelength is 220 nm; the mobile phase is 0.1% formic acid aqueous solution – 0.1% formic acid acetonitrile solution (42:58). Compared with existing technologies, UV detectors are more readily available than CAD detectors. This invention achieves quantitative detection of deoxycholic acid injection content by controlling the HPLC conditions of the UV detector. This method exhibits baseline stability, good specificity, accuracy, and precision, and is of significant importance for the quality control of deoxycholic acid injection.

Disclosed are a crystalline form of a high-stability nor-ursodeoxycholic berberine salt and a preparation method therefor, while relate to the field of pharmaceutical chemistry. The crystalline form has the following structural formula. In X-ray powder diffraction of the crystalline form, a 2θ diffraction angle has characteristic peaks at 3.54+ / -0.2 degrees, 7.13+ / -0.2 degrees, 13.14+ / -0.2 degrees, 15.95+ / -0.2 degrees, 16.40+ / -0.2 degrees, 18.64+ / -0.2 degrees, 24.90+ / -0.2 degrees, 25.76+ / -0.2 degrees and 26.30+ / -0.2 degrees. Compared with other crystalline forms of the nor-ursodeoxycholic berberine salt, the crystalline form has more excellent stability, and has a good application prospect in the preparation of high-quality solid chemical drugs.

The invention provides a lipid nanoparticle based on taurochenodeoxycholic acid modification as well as a preparation method and application thereof. The lipid nanoparticle comprises nucleic acid and a lipid carrier encapsulating the nucleic acid, the lipid carrier is prepared from the following components in percentage by mole: 40 to 65 percent of ionized lipid, 5 to 20 percent of structural phospholipid, 20 to 50 percent of sterol component and 0.5 to 5 percent of PEG (Polyethylene Glycol)-lipid, wherein the sterol component comprises cholesterol and taurochenodeoxycholic acid. By replacing cholesterol with taurochenodeoxycholic acid, the membrane order degree and fluidity of the lipid carrier are effectively adjusted, and the targeted delivery and endosome release efficiency of LNP to liver cells is remarkably improved, so that an LNP delivery system can obtain a more remarkable and lasting Lp (a) reduction effect under the same or lower dosage; by optimizing the LNP formula, it is ensured that the LNP preparation has higher controllability and reliability in the production and storage process.